Shots:
- Exact Sciences has launched Oncodetect to detect MRD across multiple solid tumors, with its efficacy supported by strong clinical validation, incl. ~5yrs. of follow-up data from the Alpha-CORRECT study
- Addiitonally, clinical & analytical validation studies across multiple solid tumors are underway, supported by strategic partnerships for multi-cancer evidence generation
- Oncodetect test provides clear “Detected” or “Not Detected” results with quantitative data to guide adjuvant therapy, assess treatment response, & monitor recurrence while tracking ~200 tumor-specific variants to detect 1 ctDNA molecule in 20,000 cfDNA molecules
Ref: Businesswire | Image: Exact Sciences
Related News:- Exact Sciences Reports the US FDA’s Approval of Cologuard Plus Test for Non-Invasive Colorectal Cancer Screening
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
